You are hereSeptember 17, 2021
Continued Efficacy and Safety of Stempeucel® for CLI
A recent STEM CELLS Translational Medicine article from researchers led by Pawan Kumar Gupta (Stempeutics Research Pvt. Ltd, Bangalore, India) reports on their continued study of the safety and efficacy of Stempeucel®, an ex-vivo cultured, pooled, human bone marrow-derived adult allogeneic mesenchymal stromal cell product, in critical limb ischemia associated with Buerger's disease. The authors report continued long-term efficacy over a period of twelve months follow-up, corroborating the result obtained in earlier phase II studies, with significant improvements observed in rest pain, systolic ankle pressure, and ankle-brachial pressure index with accelerated ulcer healing. Overall, the safe and tolerable intramuscular administration of Stempeucel® may represent an effective alternative treatment in patients with Buerger's disease.